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In  contrast  to  the  large  number  of spontaneous  mutations that  have  been 
detected in the H-2K and H-2D genes by reciprocal skin-grafting studies (1, 2), 
only one spontaneous mutation of a gene for an Ia (class II) molecule, that in the 
B6.C-H-2 bm~2 (bml 2), has been identified (3). Results of studies using the T  cells 
and antigen-presenting cells (APC) from this mutant mouse strain and from the 
strain  from  which  the  mutant  arose  (C57BL/6)  have  provided  some  of the 
strongest evidence that Ia molecules act as restriction elements for the presen- 
tation of antigens to T  cells and that Ia molecules are the products of Ir genes 
(4,  5). The further analysis of the mechanisms by which Ia molecules mediate 
"restriction" in cellular interactions and Ir gene function would be aided by the 
development of a larger number of I region mutants. 
We have recently described (6) a method for the selection of mutant cells with 
altered Ia antigenic determinants from a  cloned population of B  lymphoma-B 
cell hybridoma cells that possess potent antigen-presenting activity. Lipopolysac- 
charide (LPS)Lstimulated B cells from (BALB/c ×  A/J)F1 (CAF1) donors were 
fused with cells from the M 12.4.1  BALB/c B lymphoma cell line. The resulting 
hybridoma,  TA3,  retained  the  antigen-presenting  activity  of the  parental  B 
lymphoma  line  and  expressed  Ia  antigens  and  Ir  gene-determined  antigen- 
presenting properties of the A/J type. Mutants of TA3 were obtained by exposing 
them to ethylmethane sulfonate and subjecting the mutagenized cells to cytotoxic 
elimination with a  monoclonal anti-(a)-I-A k antibody,  followed by selection of 
cells that continued to express other ILencoded determinants by electronic cell 
sorting using a  different monoclonal antibody (positive immunoselection). We 
obtained mutants of two distinct types. One appeared to have undergone a fairly 
limited alteration since it lost only some of the I-A  k antigenic determinants. Only 
a  single example of this type was obtained (A8). The second type, represented 
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by No. 90, appeared to have lost expression of the entire I-A  k molecule but to 
have retained the I-E molecule.  Functional studies with A8  demonstrated that 
the loss of a  limited number of determinants on the I-A  k molecules of this cell 
occurred together with the loss of a  specific I-Ak-encoded restriction element. 
These results provided further support for the identification of Ia molecules as 
restriction elements in antigen recognition by T  cells and as the products of Ir 
genes. 
In  this  paper,  we present  the  serologic and  functional characterization  of a 
panel of mutants prepared from TA3 by a minor modification of the previously 
described methods.  The serologic phenotype of these mutants was investigated 
with a  large panel of monocional anti-I-A k antibodies.  The mutants  were then 
screened  for  their  ability  to  activate  a  panel  of  cloned  antigen=specific  and 
autoreactive T  cell hybridomas.  The data generated from these studies enable 
us  to  begin  to  correlate  changes  in  function  with  changes  in  the  antigenic 
structure of the Ia molecule. 
Materials and Methods 
Mice.  B10.A mice were purchased from The Jackson Laboratory, Bar Harbor, ME. 
BALB/cAnN and  CAF~ mice were obtained from the  Division of Research Services, 
National Institutes of Health. 
Antigens.  Hen egg lysozyme (HEL), purified by chromatography on the weak-cation- 
exchange resin Biorex 70 (7), was the kind gift of Dr. Eli Sercarz, University of California 
at Los Angeles and was used at  10 #g/ml in vitro. The random polymer of L-GIu  6°, L- 
Alas°, and L-Tyr  ~° (GAT), purchased from Vega Biochemicals, Tucson, AZ, was provided 
by Dr. J. Ashweli, Laboratory of Immunology, National Institute of Allergy and Infectious 
Diseases and was used at 50 #g/ml. Ovalbumin (OVA), purchased from Miles-Yeda,  Ltd., 
Rehovoth, Israel or from Sigma Chemical Co., St. Louis, MO was used at 100 #g/mouse 
for immunization and at 100-500 #g/ml in culture. Purified protein derivative (PPD) of 
Mycobacterium tuberculosis (Connaught Medical Research Laboratory, Wiliowdale, Ontario, 
Canada) was used in culture at 20 #g/ml. Keyhole limpet hemocyanin (KLH) (Calbichem- 
Behring Corp., La Jolla, CA) was used at 100 #g/ml. 
Monoclonal Anti-la Antibodies.  The following monoclonal antibodies (mAb) were used 
k  k  in these studies: 26.7.11 (anti-I-A) and  17.3.3 (anti-I-E) were produced by Ozato et al. 
and have been described (8, 9); 10.2.16 (anti-I-A  k) was produced by Oi et al. (10); a panel 
of mAb (8C,  39A,  39E,  k  39B, 39J,  39c, 40A,  40J, and 40N) specific for I-A -encoded 
determinants was the kind gift of M. Pierres (11). 
B Lymphomas and B Cell-B Lymphoma Hybridomas.  M12.4 is an Ia-positive BALB/c B 
lymphoma originally transferred into tissue culture and cloned by Kim et al. (12). M 12.4.1 
is a hypoxanthine guanosine phosphoribosyl transferase (HGPRT)-deficient variant of the 
M 12.4 line prepared by Hamano et al. (13) by selection in the presence of 6-thioguanine 
after mutagenesis with ethylmethane sulfonate (EMS). The production of the TA3 B cell- 
B lymphoma hybridoma by fusion of LPS-activated spleen cells  from CAF~ mice with 
M 12.4.1  has been described (6). 
Selection ofla Mutants from the TA3 Hybridoma.  5 x  106 TA3 cells were cultured in 25 
ml of complete media with 5 #1 of EMS (Sigma Chemical Co.);  16 h later the cells were 
harvested and washed three times to remove the  EMS.  The dose of EMS used killed 
between 30 and 50% of the cells.  The remaining cells were allowed to expand; 4-10 d 
later, they were subjected to immune lysis with the 10.2.16 or 26.7.11 anti-I-A  k mAb by 
incubating the cells at  107/ml with a  1:10 dilution of 10.2.16 culture supernatant or a 
1:100 dilution of 26.7.11 ascites for 30 min at 4°C followed by a  30 min incubation at 
37°C with complement (C) (Cedarlane Laboratories, Hornby, Ontario). This resulted in 
the death of>99% of the cells. The few remaining cells were passed over a Ficoll gradient 
to eliminate dead cells,  and allowed to expand.  These cells  were then subjected to a GLIMCHER,  SHARROW,  AND  PAUL  1575 
positive selection by electronic cell sorting (ECS)  with 26.7.11  (for cells initially treated 
with 10.2.16 and C) or 10.2.16 (for cells initially treated with 26.7.11 and C) as described 
below. The selected cells were then expanded and subjected to a second round of positive 
selection by ECS with 26.7.11  or  10.2.16,  followed by a second negative selection with 
10.2.16 or 26.7.11  and C  to eliminate wild-type cells before cloning. Cells were cloned 
by limiting dilution  in 96-well microtiter plates on a  bed of thymocytes as feeder cells. 
After 7-10 d, cells were transferred to 24-well Costar plates (Costar, Cambridge, MA), 
expanded, and analyzed by flow microfluorometry (FMF). 
FMF Analysis and ECS.  FMF analysis and ECS were performed as previously described 
(14,  15) using a  FACS II Dual Laser System (B-D FACS Systems, Sunnyvale, CA). Cells 
to be analyzed by FMF were electronically selected for viability on the basis of forward 
light scatter intensity as well as by propidium iodide exclusion as measured in the red 
fluorescence detector of the FACS II after laser excitation at 568 nm. All fluorescence 
data were obtained using logarithmic amplification; information on 2-4 x  105 viable cells 
were collected in  the green fluorescence detector after excitation at 488  nm.  Data on 
individual cells were stored and analyzed using a PDP 11/34 computer (Digital Equipment 
Corporation, Maynard, MA) interfaced to the FACS II (16).  Data are plotted as number 
of cells (y axis) versus log fluorescence intensity (x axis). 
For FMF analysis, 50 #1 (~ 108) of cells were either incubated with 20 #i of a titrated 
quantity  of fluorescein-conjugated  26.7.11  mAb (ammonium  sulfate  precipitate  from 
ascites) or were incubated  with  20 #1  of 10.2.16  or  17.3.3  culture  supernatants  or of 
purified mAb of the group derived by Pierres et ai.  (11),  followed by reaction with a 
fluorescein-conjugated Fab fragment of an affinity-purified goat anti-mouse 3'~ Fc frag- 
ment (FITC-GaMIg) (F/P  =  2.6)  (gift of Ms.  B. J.  Fowlkes,  Laboratory of Microbial 
Immunity, NIAID). All incubation steps were carried out on ice for 20-30 min, followed 
by two washes with Hank's balanced salt solution containing 3% fetal calf serum (FCS) 
and  0.1%  NaNs.  As  a  specificity control  for  staining  by  the  directly  fluoresceinated 
26.7.11  mAb, we initially used a  similarly prepared directly fluoresceinated IgM mAb 
directed at an I-A  b specificity. Since the fluorescence histogram of TA3 cells with this 
reagent did not differ from the histogram of unstained TA3 cells, subsequent experiments 
used  unstained  cells  as  the  control  for  the  26.7.11  mAb.  The  specificity control  for 
staining by anti-Ia mAb followed by fluoresceinated GaMIg was the fluorescence histo- 
gram obtained with the fluoresceinated GaMIg reagent alone. 
For ECS, cells were passed through the FACS II at a rate of 2,000 total light scatter 
signals per  second.  Sorted  cells  were  selected  on  the  basis of ranges  of fluorescence 
intensity that included TA3 cells stained with 26.7.11. Cells were also selected for viability 
on the basis of forward light scatter intensity.  The sorted cells were collected in  5-ml 
tubes containing a  1.5  ml cushion of complete media with 25% FCS. Immediately after 
sorting, the cells were reanalyzed by FMF to assess  purity, which was between 85 and 
95%. 
Production ofT Cell Hybridomas.  The procedure for the production of T cell hybridomas 
was similar to that described by Kappler et al. (17) and has been presented in detail in a 
previous report (16). Briefly, antigen-stimulated T  cell blasts prepared by a  3 d  in vitro 
stimulation with antigen of lymph node cells from immune B10.A mice were fused with 
the HGPRT-negative T  cell line BW 5147,  an AKR thymoma obtained from the Salk 
Institute Cell Distribution  Center,  La Jolla,  CA.  The GAT-specific hybridoma was the 
gift of Dr. L. Samelson, Laboratory of Immunology, NIAID; the KLH-specific hybridomas 
SKK 9.11  and SKK 23 and the OVA-specific hybridoma AODH-3.4 were the kind gifts 
of Dr.  Phillipa Marrack,  National Jewish Hospital, Denver, CO. The panel of antigen- 
specific T  cell hybridomas used in these studies is shown in Table I. 
Assay of T Cell Hybridomasfor Activity.  1 ×  105 T  hybridoma cells were co-cultured with 
varying numbers of irradiated (10,000 rad from a  l~TCesium source) B lymphoma or B 
celI-B lymphoma hybridoma cells or with 2 ×  105 irradiated (2,000 rad) spleen cells in the 
presence or absence of antigen in 0.2 ml of "fusion" medium, containing hypoxanthine, 
aminopterin and thymidine. After 2 d of culture, supernatants were collected and assayed 
for interleukin 2 (IL-2) content in a secondary culture using HT-2 cells, an IL-2-dependent 1576  IA  MUTANT  ANTIGEN-PRESENTING  CELL  LINES 
TABLE  I 
T Cell Hybridomas 
Abbreviation  Antigen specificity  Restriction 
element 
HEL(a)  Hen egg lysozyme  I-A  k 
HEL(b)  Hen egg lysozyme  I-E  k 
GAT  Poly (Glu6°Ala3°Tyr  TM)  I-A  k 
OVA No. 1  Ovalbumin  I-A  k 
OVA No. 2  Ovalbumin  I-A  k 
AODH-3.6  Ovalbumin  I-A  k 
PPD  Purified protein derivative  I-A  k 
Auto No. t  Autoreactive  I-A  k 
Auto No. 2  Autoreactive  I-A  k 
Auto No. 3  Autoreactive  I-A  d 
SKK-9.11  Keyhole limpet hemocyanin  I-A  k 
SKK-2.3  Keyhole limpet hemocyanin  I-A  k 
SKK-45.10  Keyhole limpet hemocyanin  I-A  k 
T  cell line developed by  Dr. James  Watson,  University of Auckland,  Auckland,  New 
Zealand and provided to us by Dr. Phillipa Marrack, or CTLL cells, an IL-2-dependent 
T  cell line originally developed by Dr. Kendall Smith, Dartmouth University, Hanover, 
NH  and  provided  to  us  by  Mr.  T.  Briner,  Massachusetts  Institute  of Technology, 
Cambridge, MA. HT-2 cells (2-4 ×  103) or CTLL cells (5-10 ×  103) were cultured for 
24 h in the presence of 35% primary culture supernatant and the degree of stimulation 
measured by the incorporation of [3H]thymidine (6.8 Ci/mmol; New England Nuclear, 
Boston, MA) into DNA 5-20 h later. 
Results 
Selection ofla Mutants.  We and others (18,  1  O) have previously shown that the 
fusion of normal LPS-activated B cells with the M12.4.1  drug-marked BALB/c 
B  lymphorna  results  in  B  cell-B  iymphoma  (B-B)  hybridomas  that  are  potent 
APC. TA3 is one such hybridoma, prepared by the fusion of M 12.4.1 with LPS- 
activated B cells from a CAF1  mouse. TA3 displays Ia molecules and restriction 
elements derived from the B cell partner, in that it bears I-A  k and I-E  k specificities, 
defined by a panel of monoclonal anti-Ia  k antibdies, and is able to present antigen 
to  Iak-restricted  T  cells.  To  obtain  Ia  mutant  lines  from TA3,  we  followed a 
protocol similar to that  described for the production of H-2K/D  mutants  (20, 
21) and described in detail by us recently (6). Briefly, TA3 cells treated with the 
mutagen EMS were subjected to negative immunoselection with the aI-A  k mAb 
10.2.16  in  the presence of C.  The few remaining cells (<1%) were allowed to 
expand in number and then subjected to positive selection by ECS on the FACS 
using another aI-A  k mAb,  26.7.11,  which detects a  I-A specificity distinct from 
that  recognized by  10.2.16.  It  was  from this  population  of positively selected 
cells that the initial I-A  k mutant cell line A8 was obtained. 
However, to obtain this single mutant line it was necessary to screen 6~ clones. 
To improve our yield in isolating mutants of this type, we subjected this positively 
selected population, which apparently contained <2% of the desired cell type, to 
a  second round of positive selection by ECS with the 26.7.11  mAb. Analysis of 
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also positive with  10.2.16  (i.e., appeared to be wild-type cells). This population 
was therefore subjected to a second round of immune lysis with  10.2.16 and C 
to eliminate wild-type cells. The fluorescence profile of the resulting cell popu- 
lation is shown in Fig.  1, left panels. This population does not appear to contain 
cells positive for the 10.2.16-defined determinant. "~ 20% of the cells are positive 
with the 26.7.11  antibody. 
Cells  from  this  doubly  selected  population  were  then  cloned  by  limiting 
dilution. Of 100 clones tested, 19 stained positively with 26.7.11  and 17.3.3 and 
were weakly reactive with  10.2.16.  Examples of such clones, A 19 and B 18, are 
shown in Fig. 2 as is the parental cell line, TA3. As we have previously observed 
in the study of our first such mutant, A8, the 19 lines of this type, upon repeated 
FMF  examination,  were  often  weakly  or  moderately positive  with  10.2.16, 
suggesting that this determinant had not been completely extinguished. Among 
the remaining 81  clones, only B3  appeared to be of the wild-type phenotype 
since it reacted strongly with both the 10.2.16 and 26.7.11  mAb. The other 80 
clones  reacted  with  neither  the  10.2.16  or  26.7.11  mAb.  Further  serologic 
analysis of the  19  mutants that stained strongly with 26.7.11  and weakly with 
10.2.16 is presented below. 
A second group of mutants was selected by the same approach except that the 
mAb used for the negative and positive selection steps  were reversed. Thus, 
26.7.11  was  used as  the negative immunoselecting agent and  10.2.16  as  the 
positive selecting agent. After two rounds of negative and positive immunoselec- 
tion, ---90% of the resulting cells stained positively with 10.2.16 and <5% reacted 
with 26.7.11.  The fluorescence histograms of this population are shown in Fig. 
1, right panels. 19 of 22 clones obtained by cloning this population bore the I-A  k 
determinant defined by 10.2.16 and lacked the determinant defined by 26.7.11. 
In contrast to  the weak positive reaction detected with the negative selecting 
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FIGURE  1.  FMF  analysis  of EMS-treated  TA3  cells after  double  negative selection  with 
10.2. t6 plus C and double positive selection with 26.7. I 1 (left) or double negative selection 
with 26.7.11  plus C  and  double positive selection with  10.2.16  (right).  I  ×  10  e cells were 
incubated  with  10.2.16  mAb and  then  with  the  Fab  fragment of FITC-GaMIg and  were 
analyzed by FMF. The 26.7,. 11  staining was performed with directly fluoresceinated (FITC) 
26.7.11  mAb, Control cells were incubated with the Fab fragment of FITC-GaMIg only, or, 
for comparison with FITC-26.7.11  staining, were unstained.  Preliminary experiments com- 
b  paring  cells stained  with  a  directly  fluoresceinated aI-A  mAb  revealed  no  difference in 
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FIGURE  2.  FMF analysis of TA3  cells, type A  mutants A]9  and BI8,  and type B  mutant 
A 13. Solid lines show results of cells stained with FITC-26.7.11  or of unstained cells. Dotted 
lines show results of cells stained with  10.2.16 followed by FITC-GaMIg or of control cells 
stained with FITC-GaMIg only. 
TABLE  II 
Reactivity Pattern of TA3 Mutants with a Panel of al-A  k mAb 
Antigen-presenting  aI-A  k mAb directed at determinants in four epitope groups 
cell line 
40A  40N  39B*  39E  39C  39J  40J  39A  8C 
+++  +++  +++  +++  +++  +++  +  +++  + 
_  _  ++  +/-  +++  +++  +  +++  + 
_  _  ++  +/-  +++  +++  +  +++  + 
+++  +++  ++  +++  -  _  _  +++  + 
.......  + 
TA3 
A8 
Type A mutants 
Type B mutants 
No. 90 
FMF analysis of the designated APC with the series of aI-A  k mAb described by Pierres et al. (17). 
Results are presented semiquantitatively: (-) no staining above background, (+) weak staining above 
background,  (++)  intermediate staining above background,  (+++)  strong staining above back- 
ground, (+/-) weak staining obtained in some but not all experiments. 
*Staining with 39B varied in intensity, ranging from +/-  to +++. 
agent, 10.2.16, on the first group of mutants, this second group of mutants did 
not display any reactivity with 26.7.11, the mAb used for its negative selection. 
An example of one of these  19  mutants, A13,  is shown in Fig.  2.  2 of the 22 
clones resulting from this selection appeared to be of wild-type phenotype and 1 
clone  was  negative  for  both  I-Ak-encoded determinants.  The  first  group  of 
mutants discussed above (represented by A8, A 19, and B 18) will be referred to 
as type A mutants while the second group, exemplified by A13, will be referred 
to as type B mutants. 
Further Serologic Characterization of Type A and Type B Mutants.  Recently Pierres 
et al. (11) have produced 17 mAb specific for determinants on the I-A  k molecule. 
These mAb appear to define five different epitope groups on the I-A  k molecule, 
as determined by cross-blocking studies. We examined the serologic profile of 
the 19 type A mutants with representative mAb from four of these five groups. 
Table II demonstrates that, similar to the results obtained with A8, a determi- 4 o 
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FIGURE 3.  FMF analysis of TA3 cells, type A mutants A 19 and B 18, and type B mutant A 13 
with selected aI-A  k mAb. The 40 A and 39B mAb are in Pierres' (11)  epitope group I  and 
the 39C and 39J mAb in epitope group II. Staining procedures were the same as used for the 
10.2.16 mAb. Control cells were reacted with FITC-GaMIg only. 
nant(s) recognized by two mAb (40A and 40N) of the group defined by 40A, 
40N,  39B, and 39E, is absent on the surface of all of these mutants. The third 
antibody of this group, 39B, often reacts strongly with the mutant cells and the 
fourth,  39E,  resembles  10.2.16  in  that  it reacts weakly with the mutant cells. 
The  antigenic determinants defined by  mAb of the  remaining three  groups 
appear to be present on the 19 type A  mutant cell lines at levels equal to their 
expression on TA3 cells. Fig. 3 illustrates FMF patterns of two type A  mutants 
with three of these mAb. 
We have observed that there is considerable variability in the intensity of the 
staining of type A mutants with 39B. 39B shows variability in staining of type A 
mutants both from mutant to mutant and in the same mutant line from day to 
day, ranging from moderately reactive to strongly positive.  As already noted, 
10.2.16  also  displays variability  in  its  degree of staining of type A  mutants, 
although of a more modest degree. Neither 40A nor 40N, which are in the same 
epitope group as 39B, display such variability. They uniformly fail to react with 
type A mutants. Similarly, the mAb of the other groups show quite reproducible 1580  IA  MUTANT  ANTIGEN-PRESENTING  CELL  LINES 
positive reactions with type A mutants. 
The serologic profiles of all the  19 type A  mutants,  therefore,  appear to be 
very similar.  The results suggest that the mutation(s) may involve the alteration 
or loss of a portion of one epitope of the I-A  k class II molecule. 
The  panel  of anti-I-A k mAb  was  also  used  to  examine  two  of the  type  B 
mutants (A5 and A 13). The serologic profiles of the type B mutants are shown 
in Table II; Fig. 3 illustrates FMF profiles of A13. The determinant(s)recognized 
by mAb of the 40A, 40N, 39B, and 39E epitope group as well as the determinants 
defined by the  8C  and  39A  mAb are  present  on A13  at levels equal  to their 
expression on TA3 cells. A determinant(s) defined by the three mAb (39C, 39J, 
40J) of the second epitope group is absent on the surface of A5 and A13. The 
type B  mutation(s)  thus appear  to involve the  loss or alteration  of a  different 
epitope of the  I-A  k class  II  molecule than  is  affected  in  the  type A  mutants. 
Furthermore,  it appears to involve an entire epitope as opposed to a portion of 
one. 
Mutant  90  has been described previously. Based on its failure to react with 
both the  10.2.16 and 26.7.11  mAb as well as with any of the Pierres' (11) mAb 
except 39A, we concluded that it had probably lost expression of the I-A  k class 
II molecule. The  weak reaction of 39A with mutant  90 is not surprising  since 
this  mAb  has  been  shown  to  cross-react  weakly on  the  I-Ad-encoded class  II 
molecule. Mutant 89, used in some experiments, is phenotypically similar to No. 
90. Both Nos. 89 and 90 react with  17.3.3, indicating that they express an I-E k- 
encoded class II molecule. 
Functional Analysis of the Mutants.  To test the functional activity of the mutant 
lines,  we assembled a  panel  of cloned B10.A T  cell hybridomas specific for a 
variety of foreign antigens in the context of I-Ak-encoded restriction  elements. 
A  list of these hybridomas is shown in Table I.  Selected type A  mutants  were 
tested against a panel of antigen-specific and autoreactive I-Ak-restricted T  cell 
hybrids to determine the extent of the loss of APC function that had occurred 
with the alteration  of the Ia molecule. Table III demonstrates that all of these 
type  A  mutants  are  effective in  stimulating  three  such  I-Ak-restricted  T  cell 
hybridomas, two of which were specific for KLH and one for OVA. In contrast, 
none  of these  mutants  stimulated  responses  of five additional  I-Ak-restricted 
antigen-specific T cell hybridomas, including hybridomas specific for HEL, OVA, 
PPD, and KLH. Each mutant was active in presenting HEL to the I-Ek-restricted 
T  cell hybridoma HEL(b). 
Although these results suggested that the type A mutants were similar to one 
another functionally as well as antigenically, a study of their capacity to stimulate 
three additional hybridomas raises the possibility that the mutants are different 
from one another.  A8, A 19, and B 13 stimulated responses by an I-A k-restricted 
GAT-specific T  cell hybridoma and by two I-A k-specific autoreactive hybridomas. 
By  contrast,  B18  and  C13  were  either  weakly  or  nonstimulatory  for  these 
hybridomas.  All  of these  lines  stimulated  an  autoreactive  T  cell  hybridoma 
specific for an I-A d determinant (Table IV). 
We next  examined  the  antigen-presenting  activity of several of the  type B 
mutants,  including A5, A2, and A 13. The results are shown in Table V. These 
mutants failed to present antigen to any of the panel of I-Ak-restricted antigen- GLIMCHER,  SHARROW,  AND  PAUL 
TABLE  III 
Antigen Presentation by Type A Mutants to a Panel ofT Cell Hybridomas 
1581 
APC Line 
T Cell Hybri-  Specificity 
doma  TA3  A8  A19  BI3  B18  C13 
HEL(a)  HEL:I-A  k  34,400  0  0  0  132  81 
OVA No. 1  OVA:I-A  k  14,316  480  628  276  0  0 
OVA No. 2  OVA:I-A  k  84,586  1,864  374  1,032  985  972 
PPD  PPD:I-A  k  29,727  85  220  135  0  0 
SKK 9.11  KLH:I-A  k  69,798  NT  283  288  155  NT 
SKK 2.3  KLH:I-A  ~  26,924  NT  11,805  26,238  8,596  NT 
SKK 45.10  KLH:I-A  k  124,464  NT  101,068  114,068  56,440  NT 
AODH 3.4  OVA:I-A  ~  74,779  NT  60,294  23,432  14,213  NT 
HEL(b)  HEL:I-E k  76,714  104,554  68,841  74,082  84,406  101,012 
105 T hybridoma cells were co-cultured with the designated irradiated (10,000 rad from a IS~Cesium 
source) APC in the presence or absence of the relevant antigen, HEL (10 #g/ml), OVA (300 #g/ml 
for OVA Nos. 1 and 2; 500 #g/ml for AODH 3.4), PPD (25 #g/ml), KLH (500 #g/ml), in 0.2 ml of 
complete medium. After 1-2 d of culture, supernatants were collected and assayed for IL-2 content 
in a secondary culture of HT-2 or CTLL cells. 2-10 ×  l0  s HT-2 or CTLL cells were cultured for 
24 h in the presence of 35% primary culture supernatant and the degree of stimulation  measured by 
the incorporation of [SH]thymidine into DNA. Results are expressed as cpm stimulated by superna- 
tams obtained in the presence of antigen minus that obtained in the absence of antigen. Varying 
numbers of APC of each type were  used. Only the maximum response obtained is shown. These 
were generally achieved with 104 APC per well. NT, not tested. 
TABLE  IV 
Two Auto-l-A*-reactive and One Antigen-specific I-A*-restricted T Cell 
Hybridoma Can Be Activated by Only Some Type A Mutant APC 
T cell hybridoma 
APC Line  Auto No. 1  Auto No. 2  GAT  Auto No. 3 
(I-A  t')  (I-A  k)  (GAT:I-A  k)  (I-A  a) 
TA3  52,903  105,668  27,432  35,508 
No. 90  4,979  1,533  0  NT 
A8  25,124  53,352  17,351  34,073 
AI9  40,317  73,739  31,459  6,211 
BI3  32,124  64,514  39,664  35,908 
BI8  879  13,586  302  18,607 
C13  202  265  849  70,899 
Assay performed as detailed in legend to Table III. APC were used at 
several cell numbers in these cultures, generally l0  s  , 104  , and 105  . Only 
the maximum Acpm is presented here. GAT was used at 50 #g/ml. NT, 
not tested. 
specific T  cell hybridomas or  to  stimulate the  autoreactive I-Ak-specific T  cell 
hybridomas over a  wide range of numbers of APC (only the  104 dose is shown 
here, for simplicity). They were able, however, to use their I-Ek-encoded restric- 
tion  elements  to  activate  the  HEL-specific  I-Ek-restricted  T  cell  hybridoma 
HEL(b), indicating that type B  mutation(s) had not affected a  more generalized 
antigen-presentation function. The  functional results obtained with the type A 
and B  mutants are summarized in Table VI. 1582  IA  MUTANT ANTIGEN-PRESENTING CELL LINES 
TABLE  V 
Antigen Presentation by Type B Mutants to a Panel of T Cell Hybridomas 
T  Cell hybridoma  Specificity 
APC line 
TA3  A5  A2  A13 
HEL(a)  HEL:I-A  k  107,524  642  107  90 
OVA No.  1  OVA:I-A  k  89,389  168  216  118 
SKK 9.11  KLH:I-A  ~  26,804  146  46  60 
SKK 2.3  KLH:I-A  k  20,050  50  131  35 
SKK 45.10  KLH:I-A  k  64,169  286  407  109 
AODH 3.4  OVA:I-A  k  31,121  329  162  184 
GAT  GAT:I-A  k  75,177  468  417  NT 
Auto No.  1  I-A  k  52,903  704  NT  NT 
Auto No. 2  I-A  k  53,123  206  NT  675 
Auto No. 3  I-A  d  63,523  47,044  68,483  19,421 
HEL(b)  HEL:I-E  ~  116,762  111,146  95,039  89,233 
Assay performed as detailed in legend to Tables III and IV. Results are expressed as cpm stimulated 
by supernatants obtained in the presence of antigen minus cpm stimulated by supernatants obtained 
in the absence of antigen. NT, not tested. 
Discussion 
We  have  recently  described  (6)  a  protocol  that  allows  the  selection  and 
propagation  of hybrid cells with Ia mutations from a  homogeneous population 
of functional APC. In this paper we have used a modification of that method to 
allow us to select more such limited loss mutants.  The biochemical nature of the 
alterations  that  have occurred  in  these mutants  is not  yet known,  but we can 
tentatively attribute the type A mutant(s) to effects on the A~ chains and the type 
B  mutation(s)  to  effects  on  the  A~  chain.  These  assignments  are  based  on 
knowledge of which  I-A  k chain  is principally  responsible for the expression  of 
specific antigenic determinants.  Thus, Frelinger eta]. 2 have assigned specificities 
recognized by some anti-I-A k mAb to either A~ or A~ chains both by using these 
Ab to inhibit the proliferative responses of a panel of (k x  b)F~ ailoreactive and 
antigen-specific  T  cell  clones  as  well  as  by  performing  two-dimensional  gel 
electrophoresis on the Ia molecules precipitated by these Ab from F~ cells. Their 
results indicate that  10.2.16, 40N, 39B, and 39E define determinants on the A~ 
chain while mAb 26.7.11,39J, and 40J recognize specificities on the A~ molecule. 
Silver et al.  (22) and  Kupinski et al.  (23) had previously demonstrated that  the 
10.2.16  determinant  is on  the  A~ chain.  It is most likely then  that  the  type A 
mutants have sustained an alteration  in the An chain rather than the loss of this 
molecule since determinants  10.2.16 and 39B are present at some level in these 
mutants,  whereas  40N  is  not detectable.  Recent preliminary  results  using  the 
10.2.16 mAb as an immunoprecipitating agent (D. J. McKean and L. Glimcher, 
unpublished  observations)  reveal  the  presence  of an  An  chain  in  the  type  A 
mutant A 19. 
However, we cannot  exclude the possibility that  the  type A  mutation(s)  has 
occurred in  a  regulatory  gene,  resulting  in  the diminished  synthesis of the A n 
2 Frelinger,  J. G., M. Shigeta, A.J. Infante, P. A. Nelson, M. Pierres, and C. G. Fathman. Multiple 
functional sites on a single Ia molecule defined using T cell clones  and chain-specific  anti-Ia antibodies. 
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polypeptide chain.  If this were so, the unaltered  A  t  chain,  produced in smaller 
than  normal  amounts,  could  combine  with  either  the  A~  chain  to  form  a 
"parental"  I-A class II molecule or with the A~ chain to form a hybrid I-A class 
II  molecule  (24).  If the  A~A~ molecule  differs  from  the  A~A~ and  the  A~A~ 
molecules and exhibits the determinants  recognized by 10.2.16,  39B, and  39E 
but not those recognized by 40N (and presumably 40A), then the phenotype of 
the type A mutants could be explained without the need to postulate a structural 
mutation in the A~ gene. The variability observed in the intensity of the staining 
by 39B and  10.2.16 might be attributed to the stage in the cell cycle when these 
lines  were examined  since  it  has  been  clearly  shown  that  the  amount  of cell 
surface Ia molecule varies with the stage in cell cycle (25). 
The biochemical event leading to the type B mutation may have been the loss 
of or greatly diminished synthesis of the An chain. Absence of expression of this 
chain might be secondary to a deletion of the entire gene segment encoding the 
A~ chain  or could be secondary to a  point  mutation  in a  regulatory gene that 
prevents synthesis.  Alternatively, a  point mutation  may have occurred that has 
led to a  drastic change in  the structure  of the A~ chain  and the resulting Aa~ 
molecules with consequent loss of reactivity with all the A~ chain-specific mAb. 
To the extent that  the  type B  mutants  have been studied functionally,  they 
resemble each other, just as they do antigenically.  In particular,  type B mutants 
have thus far lacked the capacity to present antigen to any I-Ak-restricted T  celt 
hybridoma or  line.  Since each  mutant  line  was obtained  from  the same EMS- 
treated  cell  population,  they  could  represent  clones  resulting  from  a  single 
mutational  event.  Type A  mutants  appear  seroiogically  like  one another  but 
some evidence for functional  diversity exists.  Thus,  two type A  mutants,  B18 
and C13, do not present GAT to an  I-Ak-restricted GAT-specific T  cell hybri- 
doma and stimulate two auto-I-Ak-specific T  cell hybridomas poorly or not at all. 
By contrast,  other type A  mutants  (A8,  A19,  and  B13)  stimulate  these three 
hybridomas quite well.  It should also be noted that some I-Ak-restricted  T  cell 
clones specific for KLH and OVA are stimulated by each of the type A mutants 
while other I-Ak-restricted T  cell clones for specific for these same antigens are 
not  stimulated  by  these  mutants.  This  strongly  suggests  that  the  antigenic 
determinants (epitopes) on these complex proteins which different T  cell clones 
recognize differ from one another. 
An understanding  of the mutational  events leading to the altered  I-A  k mole- 
cules expressed by the type A and type B mutants will require structural analysis 
of both  these  Ia  antigens  and  of the  genes  that  specify the  chains  of these 
molecules. Such studies are now in progress. 
Although  we do not yet have evidence concerning  the  nature  of structural 
changes, if any, of the I-A class II molecules in these mutant cell lines, it is useful 
to consider the functional properties of Ia molecules in order to appreciate the 
potential  effects of structural  changes  in  them.  Ia  molecules act as restriction 
elements, in that they are corecognized, with antigen, by antigen-specific T  cells 
(see references 26 and 27 for a review). Thus, the Ia molecules should possess a 
site complementary to a combining region of a T  cell receptor. This site on the 
Ia  molecule has  recently  been  designated  the  histotope  (28).  The  number  of 
distinct histotopes a  given  Ia molecule possesses is unknown.  A  mutation in the GLIMCHER,  SHARROW,  AND  PAUL  1585 
histotope of an Ia molecule could impair its ability to be corecognized by some, 
or possibly all, T  cells primed against antigens that are presented together with 
the comparable wild-type Ia molecule. This would be particularly likely if there 
were but a single histotope on each Ia molecule and if all T cells that corecognized 
that histotope used structurally similar recognition sites for that purpose. Thus, 
if type B mutants are not based on a failure to express the A~ chain, they might 
very well represent mutations within the histotope of the I-A  k molecule. 
As  a  result  of the  study of Ia  molecules as  Ir  gene products,  it  has  been 
proposed that they possess a  second class  of sites through which they interact 
with  antigen  in  the  construction  of putative  antigen-Ia  molecule complexes. 
Although only limited direct evidence has been obtained for the existence of 
such  complexes, detailed  study of the  fine  specificity of T  cell  responses  to 
peptide antigens (29-31) strongly suggests that antigen and restriction elements 
interact.  A  similar conclusion has been  reached from the finding that  T  cell 
responsiveness is determined by the product of the concentration of antigen and 
the number of Ia  molecules on  APC,  implying that  the activating agent is  a 
complex of antigen and Ia molecule (32). This second class of sites on Ia molecules 
has been designated desetopes (28).  Mutations within a  desetope would have 
obvious effects on the function of Ia molecules as Ir gene products. Whether a 
given Ia molecule has one or more desetopes, it is likely that a mutation within 
the domain of a desetope might be selective in terms of its consequences for the 
capacity of the mutant cells to present distinct antigens, since a given Ia molecule 
must be able to interact with a wide range of structurally distinct foreign antigens. 
Changes in  the structure of the desetope might impair the capacity of the Ia 
molecule  to  interact  with  antigens  of one  structural  type  without  effecting 
interactions with structurally distinct antigens. Since type A  mutants retain the 
capacity to present some but not all antigens that I-A  k molecules of the wild type 
can  present,  these  mutations  would  be  good  candidates  to  occur within  the 
desetope. On the other hand, since some type A mutants fail to stimulate auto- 
I-Ak-specific T  cell hybridomas, the possibility that the mutation has occurred in 
the histope, the site recognized by the T  cell, remains strong. Furthermore, one 
must also be aware that either (or both) the type A  or type B  mutations may 
occur outside these putative sites but nonetheless lead to structural alterations in 
the molecule that preclude its function in antigen presentation without reference 
to the structure of the antigen. 
Summary 
An improved method is described for selecting mutant cells with an altered 
pattern of Ia antigenic determinants and antigen-presenting properties from an 
homogeneous population of functional antigen-presenting cells (APC). The APC 
line used, TA3, was a somatic cell hybrid obtained by fusing normal heterozygous 
H-2  am B cells with a drug-marked variant of a BALB/c B lymphoma line. Two 
phenotypic groups of mutants were obtained by this method. Serologic analysis 
with a panel of anti-I-A  k monoclonal antibodies suggested that the change in the 
first group of mutants (type A  mutants) involved the alteration of a portion of 
one epitope of the I-A  k molecule while in the se/cond group of mutants (type B), 
an alteration of a  different Ia epitope group bad occurred. Functional studies 1586  IA  MUTANT  ANTIGEN-PRESENTING CELL  LINES 
using  a  panel  of cloned  antigen-specific  and  autoreactive  T  cell  hybridomas 
demonstrated that the loss of a  limited number of I-A  k determinants in the type 
A  mutants correlated with  the loss of some but not all I-Ak-encoded restriction 
elements,  while  the  type  B  mutation(s)  resulted  in  the  ablation  of all  I-A  k- 
restricted APC functions tested. These mutations may occur in the region of the 
Ia molecule that interacts with the T  cell receptor (the histope) or in a postulated 
region that  interacts with antigen (the desetope).  The finding that both type A 
and  B  mutations  lead  to  loss  in  the  capacity  to  be  corecognized  with  many 
different  antigens  by  I-Ak-restricted  T  cell  hybridomas  suggests  that  the  Ia 
molecule may possess very few distinct  histotopes and/or  desetopes or that  the 
tertiary  structure  of the  Ia molecule  is crucial  in  the  formation of these  sites. 
Alternatively, the mutations, particularly the type B  mutations, may have led to 
the failure of expression of an entire a  or/3 chain. 
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manuscript. 
Received  for publication 27June 1983 and in revised  form 3 August 1983. 
References 
1.  Klein, J.  1978.  H-2 mutations: their genetics and effect on immune functions. Adv. 
hnmunol.  26:56. 
2.  McKenzie, I. F. C., T. Pang, and R. V. Blanden.  1977. The use of H-2 mutants as 
models for the study of T  cell activation, hnmunol.  Rev. 35:181. 
3.  McKenzie,  I.  F.  C.,  M.  S.  Sandrin,  G.  M.  Morgan,  M.  M.  Henning,  and  R.  W. 
Melvold.  1980. Mutation in the I-A subregion of the murine H-2 complex, hnmuno- 
genetics. 11 : 103. 
4.  Fathman, C. G., M.  Kimoto, R. Melvold, and C. S. David.  1981.  Reconstruction of 
h" genes, Ia antigens and mixed lymphocyte reaction determinants by gene comple- 
mentation. Proc. Natl. Acad. Sci. USA. 78:1853. 
5.  Michaelides, M., M. Sandrin, G. Morgan, I. F. C. McKenzie, R. Ashman, and R. W. 
Melvold.  1981. Ir gene function in an I-A subregion mutant B6.C-H-2  bmj2. J. Exp. 
Med.  153:464. 
6.  Glimcher, L., T. Hamano, R. Asofsky, D. H. Sachs, M.  Pierres, L. Samelson, S. V. 
Sharrow, and W. E. Paul.  1983. Ia mutant functional antigen-presenting cell lines. J. 
Immunol.  130:2287. 
7.  Adorini, L., M. Harvey, A. Miller, and E. Sercarz. 1979. Fine specificity of regulatory 
T  cells.  II. Suppressor and helper T  cells  are induced by different regions of hen 
egg-white lysozyme in a genetically nonresponder mouse strain.J. Exp. Med. 150:293. 
8.  Ozato, K., N. Mayer, and D. H. Sachs.  1980.  Hybridoma celt  lines secreting mono- 
clonal antibodies to mouse H-2 and Ia antigens. J. Immunol.  124:533. 
9.  Ozato, K., S. L. Epstein, P. Henkart, T. H. Hansen, and D. H. Sachs.  1981. Studies 
on monoclonal antibodies to mouse MHC products. Transplant.  Proc. XIII:958. 
10.  Oi, V. T., P. P.Jones, J. w. Goding, L. A. Herzenberg, and L. A. Herzenberg. 1978. 
Properties of monoclonal antibodies  to  mouse  Ig allotypes,  H-2, and  Ia antigens. 
Curr. Top. Microbiol. hnmunol.  81:115. 
11.  Pierres, M., C.  Devaux, M.  Dosseto, and S.  Marchetto.  1981.  Clonal analysis of B- 
and T-cell responses to Ia antigens. I. Topology of epitope regions on I-A  ~ and I-E  k GLIMCHER, SHARROW,  AND  PAUL  1587 
molecules analyzed with 35 monoclonal antibodies, hmnunogenetics.  14:481. 
12.  Kim, K.J., C. Kanallopoulous-Langevin, R. M. Merwin, D. H. Sachs, and R. Asofsky. 
1979.  Establishment and  characterization  of BALB/c  lymphoma lines with  B cell 
properties.J, lmmunol.  122:549. 
13.  Hamano, T., K.J. Kim, W. M.  Leisserson, and R. Asofsky, 1982. Establishment of a 
B cell hybridomas with B cell surface antigens. J. hnmunol.  129:1403. 
14.  Bonnet, W. A., H. R. Hulett, R. G. Sweet, and L. A. Herzenberg. 1972. Fluorescence- 
activated cell sorting. Rev. Sci. Instrum.  43:404. 
15.  Segal,  D.  M.,  S.  O.  Sharrow, J.  F. Jones,  and  R.  P.  Siraganian.  1981.  Fc  (IgG) 
receptors on rat basophilic leukemia cells. J. Immunol.  126:138. 
16.  Miller,  M.  H., J.  C.  Powell,  S.  O.  Sharrow,  and  A.  R.  Schultz.  1978.  Rapid  data 
collection, analysis and graphics for flow microfluorometry instrumentation. Rev. Sci. 
Instrum.  49:1137. 
17.  Kappler, J. W., B. Skidmore, J. White, and P. Marrack.  1981. Antigen-inducible, H- 
2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen 
and H-2 recognition.J. Exp. Med.  153:1198. 
18.  Glimcher, L. H., T. Hamano, R. Asofsky, E. Heber-Katz, S. Hedrick, R. H. Schwartz, 
and W. E. Paul.  1982. I region-restricted antigen presentation by B cell-B lymphoma 
hybridomas. Nature (Lond.).  298:283. 
19.  Kappler, J., J.  White,  D.  Wegmann,  E.  Mustain,  and  P.  Marrack.  1982.  Antigen 
presentation by Ia  ÷ B cell hybridomas to H-2-restricted T cell hybridomas. Proc. Natl. 
Acad. Sci. USA.  79:3604. 
20.  Rajan, T. V., and E. D. Haley.  1981.  Anti-H-2 hybridoma antibodies as immunose- 
lective agents.  I.  Isolation of forward and  reverse mutations for reactivity with  a 
monoclonal antibody. Immunogenetics.  14:253. 
21.  Holtkamp, B.,  M. Cramer, H. Hemke, and K. Rajewsky.  1981. Isolation of a cloned 
cell  line expressing variant H-2K  k using fluorescence-activated cell sorting. Nature 
(Lond.).  289:66. 
22.  Silver, J., S. L. Swain, and J. J. Hubert. 1980. Small subunit of I-A subregion antigens 
determines the allospecificity recognized by a  monoclonal antibody. Nature (Lond.). 
286:272. 
23.  Kupinski, J.  M.,  M.  L.  Plumkett,  and J.  H.  Freed.  1983.  Assignment of antigenic 
determinants to separated I-A  k chains. J. hnmunol.  130:2277. 
24.  Fathman, C. G., and M.  Kimoto.  1981.  Studies utilizing T  cell clones:  Ir genes, Ia 
antigens and MLR-stimulating determinants, hnmunol.  Rev. 54:57. 
25.  Monroe, J.  G.,  and J.  C.  Cambier.  1983.  Level  of mIa expression  on  mitogen- 
stimulated murine B lymphocytes is dependent on position in cell cycle. J. Immunol. 
130:626. 
26.  Benacerraf, B.,  and  R.  Germain.  1978.  The immune response genes of the major 
histocompatibility complex, hnmunol.  Rev.  38:70. 
27.  Schwartz, R. H.  1982. Functional properties of I region gene products and theories 
of immune response (Ir) gene function. In Ia Antigens. S. Ferrone and C. S. David, 
editors. CRC Press, Inc., Boca Raton, Florida.  161-218. 
28.  Heber-Katz, E.,  D.  Hansburg, and  R.  H. Schwartz.  1983.  The Ia molecule of the 
antigen-presenting cell plays a critical role in immune response gene regulation of T 
cell activation. J. Mol. Cell. hnmunol.  1:3. 
29.  Matis,  L.  A.,  D.  Longo,  S.  M.  Hedrick,  C.  Hannum,  E.  Margoliash,  and  R.  H. 
Schwartz.  1983.  Clonal analysis of the major histocompatibility complex restriction 
and the fine specificity of antigen recognition in the T  cell proliferative response to 
cytochrome c. J. hnmunol.  130:1527. 
30.  Barcinski,  M.  A.,  and  A.  S.  Rosenthal.  1977.  Immune response gene  control  of 1588  IA  MUTANT  ANTIGEN-PRESENTING CELL  LINES 
determinant selection. I. Intramolecular mapping of the immunogenic sites on insulin 
recognized by guinea pig T  and B cells.J. Exp. Med. 145:726. 
31.  Thomas, D. W., K. H. Hsich,J. H. Schwartz, and G. D. Wilner. 1981. Fine specificity 
of genetic regulation of guinea pig T  lymphocytes responses to angiotensin  II and 
related peptides. J. Exp. Med.  153:583. 
32.  Matis,  L. A., L. H. Glimcher, W. E. Paul, and R. H. Schwartz.  1983. The magnitude 
of response of histocompatibility-restricted T  cell clones is a function of the product 
of the concentrations of antigen and Ia molecules. Proc. Natl. Acad. Sci. USA. In press. 